Table 5 Relationship between of IL1B expression and clinical characteristics of patients with CESC
Gene | Characteristics | Total (N) | Odds ratio (OR) | P value |
|---|---|---|---|---|
IL1B | Age (≤ 50 vs. > 50) | 304 | 1.043 (0.902–1.209) | 0.573 |
BMI (≤ 25 vs. > 25) | 259 | 1.136 (0.966–1.339) | 0.124 | |
Menopause status (Pre vs. Peri and Post) | 231 | 1.121 (0.949–1.331) | 0.183 | |
Histological type (adenosquamous vs. squamous cell carcinoma) | 304 | 0.489 (0.361–0.640) |  < 0.001 | |
T stage (T1 and T2 vs. T3 and T4) | 241 | 0.719 (0.572–0.900) | 0.004 | |
N stage (N0 vs. N1) | 193 | 1.045 (0.857–1.284) | 0.668 | |
M stage (M0 vs. M1) | 126 | 1.073 (0.715–1.731) | 0.751 | |
Clinical stage (stage I and stage II vs. stage IV and stage III) | 297 | 0.846 (0.717–1.000) | 0.048 | |
Histologic grade (G1 and G2 vs. G4 and G3) | 272 | 0.892 (0.763–1.041) | 0.149 | |
Primary therapy outcome (SD and PR and CR vs. PD) | 217 | 0.758 (0.588–0.980) | 0.031 | |
Radiation therapy (yes vs. no) | 304 | 0.977 (0.847–1.130) | 0.756 |